Matinas BioPharma Holdings (MTNB) Operating Leases (2018 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Operating Leases of $1.2 million for Q1 2026, down 38.08% year-over-year from $1.9 million in Q1 2025, and down 12.25% quarter-over-quarter from $1.3 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Operating Leases (2018 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Operating Leases for 9 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 38.08% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 38.08% YoY), while the FY2025 annual figure was $1.3 million, down 36.34% from the prior year.
- Operating Leases declined to $1.2 million in Q1 2026 per MTNB's latest filing, from $1.3 million in the prior quarter.
- Across five years, Operating Leases topped out at $4.2 million in Q3 2022 and bottomed at $1.2 million in Q1 2026.
- Historically, Operating Leases has averaged $2.9 million across 5 years, with a median of $3.2 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Leases rose 24.22% — and 2025, when it plunged 47.31%.
- Matinas BioPharma Holdings' Operating Leases stood at $3.5 million in 2022, then retreated by 18.57% to $2.9 million in 2023, then declined by 26.45% to $2.1 million in 2024, then sank by 36.34% to $1.3 million in 2025, then fell by 12.25% to $1.2 million in 2026.
- Business Quant data shows MTNB's Operating Leases at $1.2 million in Q1 2026, $1.3 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.18 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | 2.32 Mn |
| Jun 30, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 2.12 Mn |
| Sep 30, 2024 | 2.32 Mn |
| Jun 30, 2024 | 3.22 Mn |
| Mar 31, 2024 | 3.38 Mn |
| Dec 31, 2023 | 2.88 Mn |
| Sep 30, 2023 | 3.68 Mn |
| Jun 30, 2023 | 3.83 Mn |
| Mar 31, 2023 | 3.38 Mn |
| Dec 31, 2022 | 3.53 Mn |
| Sep 30, 2022 | 4.22 Mn |
| Jun 30, 2022 | 3.84 Mn |
| Mar 31, 2022 | 3.99 Mn |
| Dec 31, 2021 | 4.14 Mn |
| Sep 30, 2021 | 4.80 Mn |
| Jun 30, 2021 | 3.12 Mn |